Immix Biopharma Earnings Estimates, EPS & Revenue | NASDAQ:IMMX

Comments

Immix Biopharma Inc Earnings Estimates

IMMXNASDAQ

Trade with Public

$10.46

At close: Mar 12, 5:00 PM EST

$9.89

-0.57-5.44%

After Hours: 7:52 PM EST

Overview NewsEarningsOptions Analyst Ratings Insider Trades Short Interest Stock Report

Immix Biopharma Earnings Estimates, EPS & Revenue | NASDAQ:IMMX

Immix Biopharma (IMMX) is scheduled to report Q4 earnings on March 24, 2026. Analysts estimate EPS of $-0.16 and quarterly revenue of N/A.

In the most recent quarter (Q3), Immix Biopharma reported EPS of $-0.24, missing estimates of $-0.18 by 0.33%. Revenue came in at $0.00, meeting the estimate of $0.00 by 0.00%.

Immix Biopharma has missed EPS estimates in 2 consecutive quarters.

Over the last 4 quarters, Immix Biopharma has averaged an EPS surprise of 0.32% and a revenue surprise of 0.00%.

Earnings Date

Mar 24

EPS Estimate

$-0.160

Quarterly Revenue Estimate

–

Annual Revenue
(as of Sep 30)

–

Immix Biopharma Earnings History

Analyze the earnings history of Immix Biopharma using advanced sorting and filters.

Immix Biopharma (IMMX) Earnings Per Share

The chart below shows Immix Biopharma's reported EPS compared to analyst estimates over recent quarters.

Immix Biopharma (IMMX) Revenue

The chart below shows Immix Biopharma's reported revenue compared to analyst estimates over recent quarters.

FAQ

When is Immix Biopharma (NASDAQ:IMMX) reporting earnings?

Immix Biopharma (IMMX) is scheduled to report earnings on May 7, 2026. The last reported earnings were for reported on November 7, 2025 for Q3.

What were the latest earnings per share (EPS) for Immix Biopharma (NASDAQ:IMMX)?

The Actual EPS was $-0.24, which missed the estimate of $-0.18.

What were Immix Biopharma’s (NASDAQ:IMMX) revenues?

The Actual Revenue was $0.00, which hit the estimate of $0.00.

People Also Watch

Tectonic Therapeutic Inc

Kyverna Therapeutics Inc

NASDAQ:KYTX

$8.90

1.25%

Ironwood Pharmaceuticals Inc

NASDAQ:IRWD

$3.38

-8.15%

Immix Biopharma Earnings Estimates, EPS & Revenue | NASDAQ:IMMX

Immix Biopharma (IMMX) is scheduled to report Q4 earnings on March 24, 2026. Analysts estimate EPS of $-0.16 and quarterly revenue of N/A.

In the most recent quarter (Q3), Immix Biopharma reported EPS of $-0.24, missing estimates of $-0.18 by 0.33%. Revenue came in at $0.00, meeting the estimate of $0.00 by 0.00%.

Immix Biopharma has missed EPS estimates in 2 consecutive quarters.

Over the last 4 quarters, Immix Biopharma has averaged an EPS surprise of 0.32% and a revenue surprise of 0.00%.

Earnings Date

Mar 24

EPS Estimate

$-0.160

Quarterly Revenue Estimate

–

Annual Revenue
(as of Sep 30)

–